Document Detail


Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.
MedLine Citation:
PMID:  25068444     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVES: To analyse the relationship between an automated thrombin generation test, the endogenous thrombin potential (ETP), and other hypercoagulability markers, with vascular involvement in patients with Behçet's disease (BD). Patients and methods. We analysed 56 BD patients (30 men; mean age, 34.4 ± 14.3 years) without any known thrombophilic factor, of which 17 had previously suffered from thrombosis (deep venous thrombosis in 14 and ischaemic stroke in 3), and 56 controls matched for age and sex. Additionally, we also evaluated 20 plasma samples with an international normalised ratio (INR) between 1.5 and 5.0 obtained from patients with atrial fibrillation but without a history of embolic events that were under treatment with acenocumarol. Thrombin generation was measured as ETP with a chromogenic assay in an automated analyser. Factor VIII, von Willebrand factor antigen, prothrombin fragment 1.2, D-dimer and plasmin-antiplasmin complexes were also measured.
RESULTS: BD patients showed higher ETP values than controls (471.3± 49.3 vs. 427.5± 31.3 mA; p<0.001). Additionally, BD patients with a history of thrombosis had higher ETP values than patients without thrombosis (496.6± 36.5 vs. 460.7± 50.5 mA; p<0.01). Factor VIII and von Willebrand factor antigen were also elevated in BD patients, but only von Willebrand factor antigen showed statistically significant differences between BD patients with and without thrombosis. Acenocumarol treatment reduced thrombin generation in BD patients in parallel to INR levels, reaching values similar to those of patients with atrial fibrillation and similar INR.
CONCLUSIONS: BD is associated with thrombosis, and increased thrombin generation (measured as ETP) is a promising marker of hypercoagulability.
Authors:
Juan-Carlos Mejía; Gerard Espinosa; Dolors Tàssies; Joan-Carles Reverter; Ricard Cervera
Related Documents :
11564954 - Neutropenia is not required for clinical remission during azathioprine therapy in infla...
19011174 - Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more ...
12853724 - Patients with chronic renal failure have abnormal small intestinal motility and a high ...
10745134 - Evaluation of crohn's disease using half-fourier rare and gadolinium-enhanced sge seque...
21128934 - High risk of cardiovascular disease in iron overload patients.
20808864 - Iga anti-beta2-glycoprotein i autoantibodies are associated with an increased risk of t...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-7-17
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  -     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-7-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The exposure to coarse, fine and ultrafine particle emissions from concrete mixing, drilling and cut...
Next Document:  Adsorption of Small Hydrocarbons on the threefold PdGa surfaces: The Road to Selective Hydrogenation...